利拉鲁肽对降低2型糖尿病患者心血管事件风险的作用研究  

Effects of Liraglutide Agonist in Reducing Cardiovascular Event Risk in Patients with Type 2Diabetes

作　　者：黄水庆[1] 陈莉[1] HUANG Shuiqing, CHEN Li(Dept. of Endocrinology, the First People＇s Hospital of Guangzhou, Guangdong Guangzhou 510180, Chin)

机构地区：[1]广州市第一人民医院内分泌科,广东广州510180

出　　处：《中国医院用药评价与分析》2018年第3期315-316,319,共3页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：广东省科学技术厅科技计划项目(No.2017ZC0324)

摘　　要：目的:探讨利拉鲁肽对降低2型糖尿病患者心血管事件风险的作用。方法:采用前瞻性研究方法,选取2014年1月—2017年1月广州市第一人民医院诊治的2型糖尿病患者90例,根据随机、盲法原则分为观察组(50例)和对照组(40例),对照组患者给予二甲双胍治疗,观察组患者对照组基础上加用利拉鲁肽,均持续治疗1年。观察两组患者的血糖指标、血压指标、体质量指数及血脂指标水平和心血管事件发生情况。结果:治疗1年后,两组患者空腹血糖、餐后2 h血糖、糖化血红蛋白及舒张压的差异均无统计学意义(P>0.05);观察组患者的收缩压、体质量指数、总胆固醇、三酰甘油及低密度脂蛋白胆固醇水平明显低于对照组,高密度脂蛋白胆固醇水平明显高于对照组,差异均有统计学意义(P<0.05);观察组患者心血管事件发生率为6.0%(3/50),明显低于对照组的17.5%(7/40),差异有统计学意义(P<0.05)。结论:利拉鲁肽持续用于2型糖尿病患者,具有明显的降血压、降血糖、调节血脂和改善心功能的作用,可降低心血管事件风险,使患者获得较好的临床治疗效果。OBJECTIVE： To probe into the effects of liraglutide agonist in reducing cardiovascular event risk in patients with type Ⅱ diabetes. METHODS： 90 patients with type 2 diabetes admitted into the First People＇s Hospital of Guangzhou from Jan. 2014 to Jan. 2017 were enrolled to be divided into observation group（ 50 cases） and control group（ 40 cases） via the principle of randomness and blindness. The control group was given metformin,while the observation group additionally received liraglutide agonist based on the control group,the treatment course was last for 1 year. The blood sugar,blood pressure,BMI,blood lipid index level and incidence of cardiovascular events of two groups were observed. RESULTS： After treatment of 1 year,there was no statistical significance between two groups in FBG,2 h blood glucose after meal,glycosylated hemoglobin and diastolic pressure（ P 0. 05）. Levels of systolic blood pressure,BMI,total cholesterol,triglyceride and LDL-C of observation group were significantly lower than those of control group,yet the HDL-C was significantly higher than that of control group,with statistically significant difference（ P 0. 05）. The incidence of cardiovascular events of observation group was 6. 0%（ 3/50）,significantly lower than that of control group[17. 5%（ 7/40） ],with statistically significant difference（ P 0. 05）. CONCLUSIONS： Liraglutide agonist has obvious effects in patients with type 2 diabetes,which can lower blood pressure and blood glucose,regulate blood lipid,improve cardiac function,reduce cardiovascular event risk and make patients get better clinical efficacy.

关 键 词：利拉鲁肽 2型糖尿病 心血管事件 

分 类 号：R977.15[医药卫生—药品]